PreDxion Bio is an early-stage healthcare company based in South San Francisco that is developing a highly scalable sensor platform (10M+ tests/day) to detect viruses and proteins, with particular emphasis on SARS-CoV-2 and biomarkers (immune markers). PreDxion Bio is backed by Y Combinator, Invest Detroit, and angel investors, and has received funding from the NIH. PreDxion Bio has been granted an FDA Breakthrough Device Designation for the development of our core localized surface plasmon resonance (LSPR) biosensor technology.
Looking for a particular Refractal employee's phone or email?
The Refractal annual revenue was $4.4 million in 2026.
Refractal is based in South San Francisco, California.
The NAICS codes for Refractal are [44831, 448, 4483, 54, 44, 541].
The SIC codes for Refractal are [73, 5944, 594, 738, 59].